Iovance Biotherapeutics Inc

Research Iovance Biotherapeutics Inc (IOVA) on Bullrun: market cap USD 1.88B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIOVA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.88B
• Financial periodFY2025
• RevenueUSD 263.50M
• Revenue growth60.6%
• Net income-USD 391.00M
• Free cash flow-USD 336.24M
• Gross margin34.3%

Valuation Snapshot

latest market cap is USD 1.88B.

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal;

Frequently asked questions

What is Iovance Biotherapeutics Inc's market cap?

Iovance Biotherapeutics Inc's market capitalization is USD 1.88B.

What does Iovance Biotherapeutics Inc do?

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.